LifeCell, An Acelity Company

acelity.com

LifeCell is now an Acelity company! Acelity is a global market leader in advanced wound therapeutics and regenerative medicine, offering innovative solutions from the hospital to home that improve the lives of patients in more than 80 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. We are the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair, and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with more than 5,800 employees around the globe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

PHENOMEX LAUNCHES BEACON SELECT™ OPTOFLUIDIC SYSTEM WITH OPTO® B DISCOVERY WORKFLOWS

PRNewswire | May 16, 2023

news image

PhenomeX Inc. the functional cell biology company, announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery. The Opto B Discovery workflows, with their cutting-edge technologies and features, enable scientists to find lead candidate antibodies tailored to their specific challenges and changing needs. Combined with the value-matched Beacon Select system, more customers may access these propriety antibody discovery...

Read More

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

news image

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More

Cell and Gene Therapy

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

news image

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

news image

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More
news image

Medical, Industry Outlook

PHENOMEX LAUNCHES BEACON SELECT™ OPTOFLUIDIC SYSTEM WITH OPTO® B DISCOVERY WORKFLOWS

PRNewswire | May 16, 2023

PhenomeX Inc. the functional cell biology company, announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery. The Opto B Discovery workflows, with their cutting-edge technologies and features, enable scientists to find lead candidate antibodies tailored to their specific challenges and changing needs. Combined with the value-matched Beacon Select system, more customers may access these propriety antibody discovery...

Read More
news image

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More
news image

Cell and Gene Therapy

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More
news image

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us